Clinically validated malaria targets (Table 1) include the targets of licensed drugs cytochrome B (CytB), dihydropteroate synthase (DHPS), DHFR-TS and haeme as well as newer targets such as ATPase4 (ATP4), elongation factor 2 (eEF2), prolyl tRNA synthetase (PRS) and PI4K. The gene discussed is MT-CYB; the disease is malaria.